The estimated Net Worth of Funds Management Lp Anson A... is at least $2.61 Milion dollars as of 22 September 2023. Funds A owns over 48,060 units of MEI Pharma Inc stock worth over $2,609,848 and over the last few years Funds sold MEIP stock worth over $0.
Funds has made over 2 trades of the MEI Pharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Funds bought 48,060 units of MEIP stock worth $329,211 on 22 September 2023.
The largest trade Funds's ever made was buying 153,600 units of MEI Pharma Inc stock on 20 September 2023 worth over $938,496. On average, Funds trades about 50,415 units every 1 days since 2023. As of 22 September 2023 Funds still owns at least 864,188 units of MEI Pharma Inc stock.
You can see the complete history of Funds A stock trades at the bottom of the page.
Over the last 12 years, insiders at MEI Pharma Inc have traded over $26,282,680 worth of MEI Pharma Inc stock and bought 597,450 units worth $2,541,200 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Leaf Ventures Ii, L.P.New L... oraz Josiah T Austin. On average, MEI Pharma Inc executives and independent directors trade stock every 91 days with the average trade being worth of $360,383. The most recent stock trade was executed by Funds Management Lp Anson A... on 22 September 2023, trading 48,060 units of MEIP stock currently worth $329,211.
mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.
MEI Pharma Inc executives and other stock owners filed with the SEC include: